< Back to previous page

Publication

Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer

Journal Contribution - Journal Article

Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and future role of preclinical models to understand resistance to androgen receptor-targeted therapies. Increasing knowledge on this resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer.
Journal: Cancers
ISSN: 2072-6694
Issue: 4
Volume: 13
Pages: 1 - 16
Publication year:2021
BOF-keylabel:yes
IOF-keylabel:yes
BOF-publication weight:2
CSS-citation score:2
Authors:International
Authors from:Higher Education
Accessibility:Open